However, in the era of scRNA-Seq, key cell subpopulations in the TME were identified to be essential for the immunotherapy response, and CXCL13+ T cells emerged as one of the most important T lymphocyte subgroups in cancer immunotherapy. The gene discussed is CXCL13; the disease is cancer.